iSpecimen to acquire Foldlab AI assets for $4.5M; $2M cash + $2.5M stock

iSpecimen Inc.

Deal: $4.5M total - $2M cash ($750K at close + $1.25M milestone payments) and $2.5M in stock.
Assets: Disease-Associated Protein Discovery AI Agent and Disease Trend Prediction/Monitoring AI Model.
Closing conditions: stockholder approval, Nasdaq listing approval, regulatory consents; proxy to be filed.
Milestone payments tied to delivery/testing/acceptance; no payment for partial performance.
Stock consideration in 5-year escrow/lock-up with no leak-out; voting rights agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.